The role of ACE inhibitors and ARBs in the treatment of COVID-19 has been a key topic for researchers since the pandemic began. This latest research represents a significant update for clinicians. 

This is believed to be the first randomized clinical trial focused on treating AAAs with an angiotensin receptor blocker.

The study's authors tracked 450 patients with uncontrolled high blood pressure.

The BRACE CORONA trial focused on the safety of taking angiotensin-converting enzyme inhibitors and angiotensin receptor blockers when hospitalized with COVID-19.

Researchers tracked more than 3,300 older patients for three years, performing clinical assessments every six months. 

The study's authors explored data from more than 28,000 patients. 

The use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) is associated with a lower risk of colorectal cancer.